In conclusion, although preliminary evidence suggests that RP mutations could provide cancer cells with alternative mechanisms to inactivate p53-mediated responses to nucleolar stress, more studies are needed on the occurrence of RP gene deletions and mutations in cancer cells and their influence on p53 stabilization and therapeutic response after treatment with ribosome biogenesis inhibitors. The gene discussed is TP53; the disease is cancer.